fUniversity of Piemonte Orientale, Novara and Unit of Neurorehabilitation and Movement Disorders, IRCCS S Maugeri, Scientific Institute of Veruno, Italy ...

Markets traded range-bound but managed to close marginally in the green, taking a breather after Tuesday’s decline. Following an initial uptick, the Nifty oscillated within a narrow range and ...

ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole ...

The most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson’s ...

Mumbai: Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, on Monday shared promising results from an ongoing phase-1 trial of ISB 2001 ...

Glenmark Pharmaceuticals’ arm, Ichnos Glenmark Innovation (IGI), shared encouraging early results from a new cancer drug being tested on patients with a difficult form of blood cancer—relapsed or ...

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that ...

They include Cipla, Lupin and Glenmark, for example. Novo Nordisk presently sells its oral semaglutide in India. Intellectual property rights (IPR) experts watch with interest, DRL’s submission ...

According to the French guidelines, very severe cases of RLS require treatment with low-dose dopamine agonists, such as pramipexole, rotigotine, or ropinirole. These drugs may also help reduce ...

The recalling firm, Glenmark Pharmaceuticals Inc., USA, in Mahwah, NJ, has been connected to several medication recalls in recent months, including recalls for five different blood pressure ...

Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...